Is Nascent Biotech Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Nascent Biotech Inc (NBIO) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Nascent Biotech Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nascent Biotech Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Nascent Biotech Inc?

Muslim investors may consider investing in Nascent Biotech Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Nascent Biotech Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Nascent Biotech Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Nascent Biotech Inc updated?

The Shariah compliance status of Nascent Biotech Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Nascent Biotech Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Nascent Biotech Inc?

You can check the latest Shariah compliance status of Nascent Biotech Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Nascent Biotech Inc. Stock Analysis NBIO

United States N/A Nano Cap

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The firm's lead candidate, Pritumumab (PTB), is a human monoclonal antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. Its other products include CLNH5 and MultiPharm. MultiPharm is a proprietary platform technology that may have additive and synergistic effects not only for cancer therapy but also for diabetes, autoimmunity, and transplantation.

Key Statistics of Nascent Biotech Inc (NBIO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

60.41K

P/E Ratio (TTM)

52 Week Range

$0.00$0.13

Market Cap

34.44K

Avg. Volume

16.79K

Dividend Yield

Financial Metrics & Statements of Nascent Biotech Inc (NBIO)

FAQ's for Nascent Biotech Inc (NBIO)

According to Musaffa’s Shariah screening methodology, Nascent Biotech Inc (NBIO) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.